Affinity Asset Advisors LLC Has $17.71 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Affinity Asset Advisors LLC lifted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 940,083 shares of the company's stock after acquiring an additional 79,684 shares during the period. Nurix Therapeutics makes up approximately 2.4% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 14th largest position. Affinity Asset Advisors LLC owned about 1.24% of Nurix Therapeutics worth $17,711,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. US Bancorp DE increased its holdings in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after buying an additional 842 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after buying an additional 877 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $207,000. KLP Kapitalforvaltning AS acquired a new position in Nurix Therapeutics during the fourth quarter worth $209,000. Finally, EntryPoint Capital LLC bought a new position in Nurix Therapeutics in the 4th quarter valued at about $266,000.

Analysts Set New Price Targets

NRIX has been the topic of a number of research analyst reports. Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Royal Bank of Canada upped their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Stephens restated an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 9th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock traded up $0.44 during trading hours on Friday, hitting $10.24. The stock had a trading volume of 1,322,027 shares, compared to its average volume of 885,096. The stock's fifty day moving average is $13.19 and its two-hundred day moving average is $18.77. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56. The stock has a market capitalization of $780.66 million, a price-to-earnings ratio of -3.54 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. The trade was a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,326 shares of company stock valued at $213,449. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.